Начало・Списък с акции・ADMA Biologics Inc

ADMA Biologics Inc

Отворен

СекторЗдравеопазване

9.47 0.64

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

9.23

Максимум

9.52

Ключови измерители
By Trading Economics
Приходи	-7.5M 38M
Продажби	9.9M 124M
P/E Средно за сектора	13.929 57.002
EPS	0.16
Марж на печалбата	30.405
Служители	640
EBITDA	-3.8M 57M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+80.66% upside

Дивиденти
By Acuity
Следващи печалби	4.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	158M 2.2B
Предишно отваряне	8.83
Предишно затваряне	9.47

Настроения в новините

By Acuity

100%

325 / 340 Класиране в Healthcare

ADMA Biologics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.08.2026 г., 20:02 ч. UTC

Social Media

ADMA Biologics shares are lower amid concerns over financial practices and potential SEC scrutiny, despite claims of an internal review clearing the company.

12.08.2026 г., 19:46 ч. UTC

ADMA Biologics shares are trading lower today, despite broader market gains following a positive inflation report. The stock remains near its one-month high.

11.08.2026 г., 22:56 ч. UTC

ADMA Biologics Inc shares are lower in after-market hours following an earlier decline. The price remains above its 20-day moving average.

7.08.2026 г., 19:46 ч. UTC

Correlated Moves

News

ADMA Biologics shares are lower following a securities fraud class action lawsuit alleging false statements and undisclosed transactions, amid broader negative market sentiment.

6.08.2026 г., 20:02 ч. UTC

News

ADMA Biologics reported second-quarter net income of $37.82 million and revenue of $124.40 million, driving shares higher during Thursday's session.

5.08.2026 г., 23:02 ч. UTC

News

ADMA Biologics reported second-quarter revenue of $124.4 million, missing expectations. Shares are lower in after-market trading following the earnings release.

4.08.2026 г., 19:46 ч. UTC

News

ADMA Biologics Inc. is trading higher, buoyed by strong momentum and a decline in crude oil prices that eases inflation concerns and supports consumer spending.

3.08.2026 г., 19:16 ч. UTC

ADMA Biologics Inc shares are higher today, continuing an upward trend since Friday amid broader market optimism following recent geopolitical developments.

31.07.2026 г., 20:06 ч. UTC

News

ADMA Biologics is declining amid a class action lawsuit alleging fraudulent activities, continuing a trend of four consecutive lower sessions.

30.07.2026 г., 19:39 ч. UTC

Correlated Moves

ADMA Biologics shares are lower following a decline in first-quarter performance, reflecting broader market sentiment amid ongoing investor concerns.

29.07.2026 г., 18:17 ч. UTC

News

Correlated Moves

ADMA Biologics will report second-quarter 2026 results on August 5, contributing to today's higher share price amid steady trading.

28.07.2026 г., 20:06 ч. UTC

News

ADMA Biologics Inc. is rising amid broader biotechnology sector strength, despite ongoing legal challenges. The stock has shown steady gains since Monday's close.

27.07.2026 г., 19:41 ч. UTC

ADMA Biologics Inc shares are higher today, continuing a strong performance since Friday. No specific news was identified to explain the gains.

24.07.2026 г., 19:26 ч. UTC

News

ADMA Biologics shares are lower amid a securities fraud lawsuit alleging inflated revenue growth and related party transactions, impacting investor sentiment.

22.07.2026 г., 18:36 ч. UTC

News

ADMA Biologics shares are lower as a class action lawsuit targets investors, alleging false statements about business practices and internal controls.

21.07.2026 г., 19:36 ч. UTC

News

ADMA Biologics Inc faces a class action lawsuit alleging securities fraud, contributing to its decline since Monday's close. Shares briefly rebounded earlier in the session.

20.07.2026 г., 19:46 ч. UTC

ADMA Biologics Inc shares are higher during Monday's session, despite fluctuations and no specific news to explain the price action since Friday's close.

Сравнение с други в отрасъла

Ценова промяна

ADMA Biologics Inc Прогноза

Ценова цел

By TipRanks

80.66% нагоре

12-месечна прогноза

Среден 17 USD 80.66%

Висок 21 USD

Нисък 12 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за ADMA Biologics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на ADMA Biologics Inc през последните 3 месеца.

Настроение

By Acuity

325 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.